Form 4: Ligand Pharmaceuticals' President and COO Sells Shares
SEC Form 4
Matthew E. Korenberg, President and COO of Ligand Pharmaceuticals, sold 18,245 shares of common stock on August 9, 2024.
Summary
- On August 9, 2024, Matthew E. Korenberg, the President and COO of Ligand Pharmaceuticals, sold 18,245 shares of the company's common stock.
- The sale was executed at a price of $98.5 per share.
- Following the transaction, Korenberg directly owns 68,368 shares of Ligand Pharmaceuticals.
Sentiment
Score: 5
Explanation: This is a neutral event. An executive selling shares doesn't necessarily indicate a negative outlook, as it could be for personal financial reasons.
Industry Context
This is a routine disclosure of an insider transaction. It's common for executives to periodically sell shares for personal financial management.
Stakeholder Impact
- The sale of shares by a high-ranking executive could potentially cause minor short-term fluctuations in the stock price, but the overall impact is likely to be minimal.
Key Dates
| Date | Description |
|---|---|
| 08/09/2024 | Date of stock sale transaction |
| 08/13/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.